-
Dicloxacillin Activity Against Intracellular S. aureus
2026-09-04
The reference study integrated THP-1 cell assays, a murine peritonitis model, and pharmacokinetic/pharmacodynamic analysis to compare dicloxacillin activity against intracellular and extracellular Staphylococcus aureus. Its central finding was that free-drug time above MIC, rather than peak concentration or total exposure alone, best predicted efficacy in both compartments, providing a framework for Gram-positive infection research.
-
KPT330 and Nuclear Export in Cas9 Precision Editing
2026-09-03
Cui and colleagues showed that selective inhibitors of nuclear export, including KPT330, can reduce CRISPR-Cas9, base-editing, and prime-editing activity by disrupting Cas9 mRNA export rather than directly inhibiting the Cas9 protein. The study identifies nuclear RNA trafficking as an additional, pharmacologically accessible layer for improving editing precision in human cells.
-
Radioiodinated Balsalazide for UC Imaging
2026-09-03
The reference study develops and evaluates radioiodinated balsalazide as a colon-associated tracer for ulcerative colitis in mice. Its combination of optimized labeling, 24-hour stability testing, and comparative biodistribution provides a practical preclinical framework for assessing disease-localized radiotracers while also highlighting important limits to clinical translation.
-
Gamithromycin: Why Serum Changes MIC Meaning
2026-09-02
Gamithromycin susceptibility is not defined by the drug and organism alone; the assay matrix can materially alter MIC interpretation. This article translates serum-conditioned evidence into practical decisions for respiratory and caprine mastitis research.
-
Temafloxacin: A Decision Framework for Assay Design
2026-09-02
Temafloxacin is a fluoroquinolone broad-spectrum antibacterial agent suited to mechanism-led antibacterial testing. This guide connects exposure, pathogen biology, assay endpoints, and lessons from antibiotic-production engineering to improve experimental decisions without conflating distinct evidence domains.
-
Caged Bioluminescent Probe for the Immunoproteasome
2026-09-01
Loy and Trader present a protocol for synthesizing and applying a cleavable, immunoproteasome-selective activity-based probe that couples a β5i-recognizing peptide with aminoluciferin. The workflow extends immunoproteasome analysis from conventional fluorescence toward plate-reader luminescence, live-cell assays, tissue-mimicking conditions, and potentially future in vivo studies.
-
Polyethylenimine Linear: PEI MW 40,000 Assays
2026-09-01
Build reproducible DNA-delivery workflows for transient gene expression, breast cancer mechanism studies, and recombinant protein production with a serum-compatible PEI formulation. This guide connects practical transfection optimization with the AC008406.3–docetaxel cuproptosis study and provides assay-specific troubleshooting.
-
WM-8014: A Practical KAT6A Inhibitor Workflow
2026-08-31
WM-8014 is a reversible, competitive KAT6A/B inhibitor for connecting acetyl-CoA-site biochemistry with cell-cycle arrest, senescence, and tumor-growth studies. This practical guide translates time-gated CRISPR findings into pharmacological assay designs, dose-timing strategies, and troubleshooting steps for cancer biology research.
-
ZK53: Human Mitochondrial ClpP Activator
2026-08-31
ZK53 enables selective activation of human mitochondrial ClpP, connecting mitochondrial proteostasis to electron transport chain failure, DNA-damage signaling, and ferroptosis sensitivity. This practical guide translates those mechanisms into biochemical, cellular, and tumor-model workflows while separating established product data from assay-development recommendations.
-
Cefepime (BMY-28142) Research Workflows
2026-08-30
Cefepime (BMY-28142) connects reproducible susceptibility testing with plasmid-transfer and central nervous system infection research. This workflow explains how to control preparation, pair phenotype with genotype, and interpret neurotoxicity and resistance signals without confusing exploratory assay results with clinical conclusions.
-
Asunaprevir: Mechanism-to-Readout HCV Analysis
2026-08-29
Asunaprevir and BMS-650032 are examined through a mechanism-to-readout framework that separates protease inhibition from cellular antiviral effects. This article also draws a carefully bounded lesson from HDAC assay design to improve interpretation of HCV RNA replication inhibition studies.
-
Computational Hapten Design for Dual Mushroom Toxin Sensing
2026-08-28
The reference study combines molecular similarity analysis and quantum chemical calculations with antibody engineering to improve balanced recognition of amatoxins and phallotoxins. Its dual-target fluorescent immunochromatographic assay detects both toxin classes in mushroom samples, addressing a major limitation of rapid methods that traditionally measured amatoxins alone.
-
Cefazedone (Refosporen): In Vitro Workflow Guide
2026-08-28
Build more reproducible Cefazedone susceptibility assays with solvent-aware preparation, phenotype-stratified controls, and MIC-to-PK interpretation. This practical guide connects Refosporen’s PBP-directed activity with workflows for respiratory, urinary, skin, and other bacterial research models.
-
Polyethylenimine Linear: PEI MW 40,000 Workflow
2026-08-27
Build reproducible DNA delivery workflows with Polyethylenimine Linear, from HEK-293 transfection to scalable recombinant protein production. This guide combines PEI-specific setup advice with a calcium-phosphate reference study to clarify how DNA concentration, reaction volume, and particle formation affect assay performance.
-
CCK-8 Inhibits IgG1 in LPS-Activated B Cells
2026-08-27
The reference study showed that sulfated cholecystokinin octapeptide suppresses proliferation, IgG1 transcription, and IgG1 production in LPS-activated primary murine B cells. Its receptor-antagonist experiments and transcription-factor analysis identify CCK2R-linked regulation of Blimp1, Pax5, Xbp1, and Bcl6 as a mechanistic framework for studying peptide-mediated control of humoral immunity.